Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Thomas McCoy Roberts, Ph.D.

Concepts

This page shows the publications Thomas Roberts has written about Humans.
Connection Strength

0.202
  1. PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-a inhibition. Proc Natl Acad Sci U S A. 2020 09 29; 117(39):24427-24433.
    View in: PubMed
    Score: 0.010
  2. CRKL Mediates p110ß-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Rep. 2017 07 18; 20(3):549-557.
    View in: PubMed
    Score: 0.008
  3. Epigenetic regulation of RTK signaling. J Mol Med (Berl). 2017 08; 95(8):791-798.
    View in: PubMed
    Score: 0.008
  4. Delivery strategies and potential targets for siRNA in major cancer types. Adv Drug Deliv Rev. 2016 09 01; 104:2-15.
    View in: PubMed
    Score: 0.008
  5. Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. J Virol. 2014 Oct; 88(20):12055-64.
    View in: PubMed
    Score: 0.007
  6. Polyoma small T antigen triggers cell death via mitotic catastrophe. Oncogene. 2015 May 07; 34(19):2483-92.
    View in: PubMed
    Score: 0.007
  7. The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type. J Virol. 2014 Sep; 88(18):10673-9.
    View in: PubMed
    Score: 0.007
  8. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A. 2011 Sep 13; 108(37):E699-708.
    View in: PubMed
    Score: 0.006
  9. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc Natl Acad Sci U S A. 2010 Jun 15; 107(24):11002-7.
    View in: PubMed
    Score: 0.005
  10. Comparing the roles of the p110a and p110ß isoforms of PI3K in signaling and cancer. Curr Top Microbiol Immunol. 2010; 347:55-77.
    View in: PubMed
    Score: 0.005
  11. The identification of zebrafish mutants showing alterations in senescence-associated biomarkers. PLoS Genet. 2008 Aug 15; 4(8):e1000152.
    View in: PubMed
    Score: 0.005
  12. Surveillance mechanism linking Bub1 loss to the p53 pathway. Proc Natl Acad Sci U S A. 2007 May 15; 104(20):8334-9.
    View in: PubMed
    Score: 0.004
  13. PI3 kinases in cancer: from oncogene artifact to leading cancer target. Sci STKE. 2006 Dec 12; 2006(365):pe52.
    View in: PubMed
    Score: 0.004
  14. PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. J Biol Chem. 2006 Aug 11; 281(32):23003-12.
    View in: PubMed
    Score: 0.004
  15. Human tumor mutants in the p110alpha subunit of PI3K. . 2006 Apr; 5(7):675-7.
    View in: PubMed
    Score: 0.004
  16. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A. 2005 Dec 20; 102(51):18443-8.
    View in: PubMed
    Score: 0.004
  17. The serine/threonine kinase cyclin G-associated kinase regulates epidermal growth factor receptor signaling. Proc Natl Acad Sci U S A. 2004 Jul 13; 101(28):10296-301.
    View in: PubMed
    Score: 0.003
  18. DEF-1/ASAP1 is a GTPase-activating protein (GAP) for ARF1 that enhances cell motility through a GAP-dependent mechanism. J Biol Chem. 2002 Mar 08; 277(10):7962-9.
    View in: PubMed
    Score: 0.003
  19. Induction of p53-independent apoptosis by simian virus 40 small t antigen. J Virol. 2001 Oct; 75(19):9142-55.
    View in: PubMed
    Score: 0.003
  20. Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas. Cell Rep. 2020 09 29; 32(13):108196.
    View in: PubMed
    Score: 0.003
  21. The activation loop in Lck regulates oncogenic potential by inhibiting basal kinase activity and restricting substrate specificity. Oncogene. 2000 Aug 17; 19(35):3961-70.
    View in: PubMed
    Score: 0.003
  22. pRB-dependent, J domain-independent function of simian virus 40 large T antigen in override of p53 growth suppression. J Virol. 2000 Jan; 74(2):864-74.
    View in: PubMed
    Score: 0.002
  23. Tangled webs: evidence of cross-talk between c-Raf-1 and Akt. Sci STKE. 1999 Dec 21; 1999(13):PE1.
    View in: PubMed
    Score: 0.002
  24. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. Oncogene. 2020 01; 39(1):50-63.
    View in: PubMed
    Score: 0.002
  25. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
    View in: PubMed
    Score: 0.002
  26. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018 12 11; 25(11):2972-2980.e5.
    View in: PubMed
    Score: 0.002
  27. Targeted Profiling of RNA Translation. Curr Protoc Mol Biol. 2019 01; 125(1):e71.
    View in: PubMed
    Score: 0.002
  28. Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. Proc Natl Acad Sci U S A. 2018 10 02; 115(40):E9325-E9332.
    View in: PubMed
    Score: 0.002
  29. Discovery of estrogen-responsive genes using an improved method which combines subtractive hybridization and PCR. Nucleic Acids Res. 1998 Aug 01; 26(15):3616-8.
    View in: PubMed
    Score: 0.002
  30. Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer. J Clin Oncol. 2018 05 01; 36(13):1339-1342.
    View in: PubMed
    Score: 0.002
  31. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 08 24; 548(7668):471-475.
    View in: PubMed
    Score: 0.002
  32. PI3K-p110a mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85a. Proc Natl Acad Sci U S A. 2017 07 03; 114(27):7095-7100.
    View in: PubMed
    Score: 0.002
  33. The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochim Biophys Acta Rev Cancer. 2017 Aug; 1868(1):123-131.
    View in: PubMed
    Score: 0.002
  34. The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11681-6.
    View in: PubMed
    Score: 0.002
  35. Transformation by Polyomavirus Middle T Antigen Involves a Unique Bimodal Interaction with the Hippo Effector YAP. J Virol. 2016 08 15; 90(16):7032-7045.
    View in: PubMed
    Score: 0.002
  36. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Gynecol Oncol. 2016 09; 142(3):548-56.
    View in: PubMed
    Score: 0.002
  37. Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 01; 19(1):22-30.
    View in: PubMed
    Score: 0.002
  38. PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. Cell Rep. 2016 06 21; 15(12):2692-704.
    View in: PubMed
    Score: 0.002
  39. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016 07; 22(7):723-6.
    View in: PubMed
    Score: 0.002
  40. Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget. 2016 Mar 15; 7(11):13153-66.
    View in: PubMed
    Score: 0.002
  41. PI3K-p110a mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene. 2016 07 07; 35(27):3607-12.
    View in: PubMed
    Score: 0.002
  42. Direct association of Grb2 with the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem. 1995 May 26; 270(21):12774-80.
    View in: PubMed
    Score: 0.002
  43. Papillomavirus E7 oncoproteins share functions with polyomavirus small T antigens. J Virol. 2015 Mar; 89(5):2857-65.
    View in: PubMed
    Score: 0.002
  44. Interaction of the protein kinase Raf-1 with 14-3-3 proteins. Science. 1994 Oct 07; 266(5182):126-9.
    View in: PubMed
    Score: 0.002
  45. The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation. Curr Biol. 2014 Oct 06; 24(19):2274-80.
    View in: PubMed
    Score: 0.002
  46. Association of polyomavirus middle tumor antigen with 14-3-3 proteins. Science. 1994 Jul 22; 265(5171):535-7.
    View in: PubMed
    Score: 0.002
  47. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014 Jul 03; 158(1):171-84.
    View in: PubMed
    Score: 0.002
  48. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A. 2014 Apr 29; 111(17):6395-400.
    View in: PubMed
    Score: 0.002
  49. Signal transduction pathways involving the Raf proto-oncogene. Cancer Metastasis Rev. 1994 Mar; 13(1):105-16.
    View in: PubMed
    Score: 0.002
  50. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110a. J Clin Invest. 2014 Apr; 124(4):1794-809.
    View in: PubMed
    Score: 0.002
  51. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013 Sep; 3(9):1030-43.
    View in: PubMed
    Score: 0.002
  52. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS One. 2012; 7(8):e44146.
    View in: PubMed
    Score: 0.001
  53. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012 Aug 02; 488(7409):106-10.
    View in: PubMed
    Score: 0.001
  54. Comparisons between murine polyomavirus and Simian virus 40 show significant differences in small T antigen function. J Virol. 2011 Oct; 85(20):10649-58.
    View in: PubMed
    Score: 0.001
  55. Characterization of an active, non-myristylated, cytoplasmic form of the lymphoid protein tyrosine kinase pp56lck. Int Immunol. 1991 Jul; 3(7):673-82.
    View in: PubMed
    Score: 0.001
  56. Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology. 2011 Jul; 141(1):50-61.
    View in: PubMed
    Score: 0.001
  57. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010 Dec 16; 468(7326):968-72.
    View in: PubMed
    Score: 0.001
  58. Histone H4K20/H3K9 demethylase PHF8 regulates zebrafish brain and craniofacial development. Nature. 2010 Jul 22; 466(7305):503-7.
    View in: PubMed
    Score: 0.001
  59. Oncogenes, growth factors, and signal transduction. N Engl J Med. 1989 Nov 16; 321(20):1383-91.
    View in: PubMed
    Score: 0.001
  60. The cellular proteins which can associate specifically with polyomavirus middle T antigen in human 293 cells include the major human 70-kilodalton heat shock proteins. J Virol. 1989 Nov; 63(11):4533-9.
    View in: PubMed
    Score: 0.001
  61. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug; 8(8):627-44.
    View in: PubMed
    Score: 0.001
  62. Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol. 2009 Apr; 21(2):199-208.
    View in: PubMed
    Score: 0.001
  63. Simian virus 40 large T antigen disrupts genome integrity and activates a DNA damage response via Bub1 binding. J Virol. 2009 Jan; 83(1):117-27.
    View in: PubMed
    Score: 0.001
  64. A non-canonical function of zebrafish telomerase reverse transcriptase is required for developmental hematopoiesis. PLoS One. 2008; 3(10):e3364.
    View in: PubMed
    Score: 0.001
  65. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008 Aug 07; 454(7205):776-9.
    View in: PubMed
    Score: 0.001
  66. A histone H3 lysine 27 demethylase regulates animal posterior development. Nature. 2007 Oct 11; 449(7163):689-94.
    View in: PubMed
    Score: 0.001
  67. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007 Jun 15; 129(6):1065-79.
    View in: PubMed
    Score: 0.001
  68. Bub1: escapades in a cellular world. . 2007 Jul 15; 6(14):1699-704.
    View in: PubMed
    Score: 0.001
  69. The p110alpha isoform of phosphatidylinositol 3-kinase is essential for polyomavirus middle T antigen-mediated transformation. J Virol. 2007 Jul; 81(13):7069-76.
    View in: PubMed
    Score: 0.001
  70. The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell. 2007 Mar 23; 128(6):1077-88.
    View in: PubMed
    Score: 0.001
  71. A genetic screen for candidate tumor suppressors identifies REST. Cell. 2005 Jun 17; 121(6):837-48.
    View in: PubMed
    Score: 0.001
  72. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004 Dec 15; 64(24):8867-75.
    View in: PubMed
    Score: 0.001
  73. Functional genetics and experimental models of human cancer. Trends Mol Med. 2004 Jul; 10(7):344-50.
    View in: PubMed
    Score: 0.001
  74. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 2003 Dec; 4(6):463-76.
    View in: PubMed
    Score: 0.001
  75. Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell. 2003 May; 3(5):483-95.
    View in: PubMed
    Score: 0.001
  76. Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells. J Biol Chem. 1999 Nov 05; 274(45):32274-8.
    View in: PubMed
    Score: 0.001
  77. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A. 1999 Mar 02; 96(5):2110-5.
    View in: PubMed
    Score: 0.001
  78. Inactivation of pRB-related proteins p130 and p107 mediated by the J domain of simian virus 40 large T antigen. Mol Cell Biol. 1997 Sep; 17(9):4979-90.
    View in: PubMed
    Score: 0.001
  79. DnaJ/hsp40 chaperone domain of SV40 large T antigen promotes efficient viral DNA replication. Genes Dev. 1997 May 01; 11(9):1098-110.
    View in: PubMed
    Score: 0.001
  80. Erythropoietin activates Raf1 by an Shc-independent pathway in CTLL-EPO-R cells. Blood. 1997 Jan 01; 89(1):55-64.
    View in: PubMed
    Score: 0.001
  81. Platelet-derived growth factor-induced formation of tensin and phosphoinositide 3-kinase complexes. J Biol Chem. 1996 Sep 20; 271(38):23452-7.
    View in: PubMed
    Score: 0.000
  82. Downregulation of Lck-mediated signal transduction by tip of herpesvirus saimiri. J Virol. 1995 Dec; 69(12):7814-22.
    View in: PubMed
    Score: 0.000
  83. Polyoma middle tumor antigen interacts with SHC protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen. Proc Natl Acad Sci U S A. 1994 Jul 05; 91(14):6344-8.
    View in: PubMed
    Score: 0.000
  84. Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor. Proc Natl Acad Sci U S A. 1992 Nov 01; 89(21):10435-9.
    View in: PubMed
    Score: 0.000
  85. Purification and initial characterization of the lymphoid-cell protein-tyrosine kinase p56lck from a baculovirus expression system. Proc Natl Acad Sci U S A. 1991 Jul 15; 88(14):6254-8.
    View in: PubMed
    Score: 0.000
  86. An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. J Virol. 1991 Jul; 65(7):3681-92.
    View in: PubMed
    Score: 0.000
  87. Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce rapid phosphorylation and activation of the proto-oncogene Raf-1 in a human factor-dependent myeloid cell line. Blood. 1991 Jan 15; 77(2):243-8.
    View in: PubMed
    Score: 0.000
  88. Stimulation via CD3-Ti but not CD2 induces rapid tyrosine phosphorylation of a 68-kDa protein in the human Jurkat T cell line. J Immunol. 1990 Jan 15; 144(2):647-52.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.